Should You Buy GlaxoSmithKline plc Or AstraZeneca plc?

After releasing disappointing results today, is GlaxoSmithKline plc (LON: GSK) still a better buy than AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineIt’s been a disappointing year thus far for investors in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), with shares in the pharmaceutical company being down 6%. This does not compare favourably to the wider market (the FTSE 100 is up 1%), nor to sector peer, AstraZeneca (LSE: AZN) (NYSE: AZN.US), which is up 23% having benefited from bid approaches from Pfizer.

A Challenging Quarter

Indeed, GlaxoSmithKline’s results released today showed that the company is struggling to come to terms with declining dales for its blockbuster inhaler, Advair. The removal of Advair from the reimbursement list of the US’s biggest prescription manager, Express Scripts, compounded falling sales for its omega 3 medicine, Lovaza, which is experiencing high levels of generic competition. The overall effect of this, as well as ongoing issues with regards to alleged bribery in China, has been a 4% reduction in revenue and a 12% fall in profit (after currency effects are removed).

A Different Story at AstraZeneca?

Meanwhile, sector peer AstraZeneca is also experiencing difficulties at present. Its patent cliff is in full-swing, with earnings for the full year expected to be 15% lower than last year, followed by a further 3% fall next year. This is in contrast to GlaxoSmithKline, which now expects flat earnings this year, with the market forecasting a rise of 9% next year.

However, investors are focused on the longer term for AstraZeneca, with the company’s strategy of acquisition in order to overcome its patent woes proving popular among investors. For GlaxoSmithKline, though, the focus is on a much shorter timeframe and the company’s enviable drugs pipeline is not the key motivator for investors right now when, in fact, it could be argued that it should be. That’s because it will be GlaxoSmithKline’s pipeline that will be the main driver of the company’s future growth.

Looking Ahead

Despite GlaxoSmithKline’s update being disappointing today, it continues to offer better growth prospects, a better valuation and a better yield than AstraZeneca. For instance, GlaxoSmithKline trades on a price to earnings (P/E) ratio of 13.5, while AstraZeneca’s P/E is 17.6. The two companies’ yields, meanwhile, are 5.4% (GlaxoSmithKline) and 3.8% (AstraZeneca), again highlighting that GlaxoSmithKline is the more attractive investment at the present time.

Certainly, the allegations regarding bribery in China are causing a certain amount of share price weakness, as are doubts regarding the loss of patent protection on key, blockbuster drugs. However, GlaxoSmithKline has a strong pipeline, growth potential, a top-notch yield and is trading at a significant discount to a key peer in AstraZeneca. As such, it appears to be a great buy at present with a bright long-term future ahead of it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »